{"id":"akkermansia-muciniphila-infliximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Immunosuppression-related complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Akkermansia muciniphila is a commensal bacterium that strengthens intestinal barrier function and promotes anti-inflammatory immune responses. Infliximab is a TNF-α inhibitor that reduces systemic inflammation. Together, they aim to restore dysbiotic microbiota and reduce inflammatory pathways implicated in inflammatory bowel disease and related conditions.","oneSentence":"A combination therapy that uses the probiotic bacterium Akkermansia muciniphila to restore gut microbiota balance while infliximab suppresses TNF-α-mediated inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:20:33.956Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)"},{"name":"Microbiota-associated inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT07415473","phase":"PHASE4","title":"Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Chinese Medical Association","startDate":"2026-04-01","conditions":"Crohn's Diseases","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Akkermansia muciniphila + Infliximab","genericName":"Akkermansia muciniphila + Infliximab","companyName":"Chinese Medical Association","companyId":"chinese-medical-association","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination therapy that uses the probiotic bacterium Akkermansia muciniphila to restore gut microbiota balance while infliximab suppresses TNF-α-mediated inflammation. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Microbiota-associated inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}